Lilly Highlights Latest Work in Diabetes Discovery and Development at 2014 European Association for the Study of Diabetes Annual Meeting

INDIANAPOLIS, Sept. 9, 2014 /PRNewswire/ -- Fifty abstracts designed to advance knowledge in diabetes science will be presented Sept. 15-19 by Eli Lilly and Company (NYSE: LLY) at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting. Notably, the company is highlighting two of its late-stage products: basal insulin peglispro and once-weekly dulaglutide. Twenty-eight of the abstracts will be presented as part of the Boehringer Ingelheim-Lilly Diabetes Alliance. EASD will take place in Vienna, Austria.

"Lilly's legacy of diabetes research continues today, and we are committed to advancing knowledge among healthcare professionals in the diabetes community," said Gwen Krivi, Ph.D., vice president, Lilly Diabetes product development. "With 382 million people worldwide affected by diabetes, our goal is to drive forward research on new and existing treatments that may provide patients with new options."

Among the data being presented at EASD are:

Dulaglutide: Among the abstracts showcased at the meeting, Lilly will give three oral presentations for once-weekly dulaglutide, an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being studied for the treatment of type 2 diabetes. Details for these and other presentations are as follows:

Basal Insulin Peglispro: Lilly will present three abstracts with pre-clinical and human mechanism of action data for its investigational basal insulin peglispro. Details for the presentations are as follows:

About Diabetes
An estimated 382 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 85 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.[1] 

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at and


This press release contains forward-looking statements about two investigational compounds, dulaglutide and basal insulin peglispro LY2605541, which are currently in development for the treatment of diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that dulaglutide and/or basal insulin peglispro LY2605541 will receive required regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

[1] International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013.

Refer to:
Candace Johnson (for dulaglutide inquiries), +1-317-755-9143,
Molly McCully (for basal insulin peglispro inquiries), +1-317-478-5423,

Eli Lilly and Company logo.

Logo -

SOURCE Eli Lilly and Company

News Provided by Acquire Media

Close window | Back to top